August 8, 2017 - Cynvenio launches its second generation PD-L1 expression test. The new blood test offers improved analytic performance over the company’s first generation PD-L1 test, enabling highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer cells recovered from a simple blood draw.
March 9, 2017 – Cynvenio will showcase its ClearID Total Insight Monitoring service at the 34th Annual Miami Breast Cancer Conference, the Young Survival Coalition (YSC) Summit, and the 27th Annual Interdisciplinary Breast Center Conference.
March 9, 2017 – Cynvenio Biosystems, Inc., a leader in personalized medicine technology and cancer diagnostics, today announced the availability of ClearID® Total Insight™ Breast Cancer, a liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient’s biological health is designed to measure immune health status and detect genetic mutations associated with cancer.
February 23, 2017 – Cynvenio and Color announces a partnership to offer the Color Test, a hereditary cancer panel that analyzes 30 genes including BRCA1 and BRCA2 with Cynvenio’s ClearID® Breast Cancer test, a specialized next-generation sequencing (NGS) panel that interrogates 27 genes for somatic mutations in breast cancer.
January 26, 2017 - Cynvenio Biosystems, Inc. and Milenia Labs announced a distribution agreement for Cynvenio’s ClearID® Breast Cancer. The agreement will make ClearID Breast Cancer exclusively available to customers through Milenia Labs and its network of 12 diagnostic centers in Mexico.
January 9, 2017 - Cynvenio has released its updated ClearID® Breast Cancer blood test. The new ClearID test identifies circulating tumor cell burden and detects emergent genetic alterations associated with resistance to therapy, and has been optimized to monitor patients with advanced breast cancer during initiation of therapy and at regular intervals following treatment.
Dr. Kristi Funk, Angelina Jolie's surgeon and co-founder of the Pink Lotus Breast Center, discusses Cynvenio's new clinical research study for women with triple negative breast cancer (TNBC).
March 3, 2016 – Cynvenio Biosystems, Inc. honors Triple Negative Breast Cancer Day by launching a clinical trial for women with triple negative breast cancer (TNBC) using the company’s non-invasive liquid biopsy technology to monitor participants and identify early signs of metastasis.
LOS ANGELES, September 16, 2014 – Cynvenio Biosystems, Inc. announces that it will be accepting payment for its ClearID Breast Cancer test under most health insurance plans including Aetna, UnitedHealth Group, Cigna, Assurant, Blue Cross/Blue Shield, Humana, Kaiser Permanente and various Health Maintenance Organizations (HMO), with the exception of Medicaid.
September 14, 2014 - Jennifer Smith of 77WABC Radio's Optimal Wellness hour, hosts the second of two interviews discussing the ClearID test. In this show focused on Breast Cancer awareness, Jennifer speaks with returning guest, Dr. Joe Bosiljevac, and Cynvenio's CEO, Andre' de Fusco.